Published Year: 2021
Global Non-Invasive Prenatal Testing (NIPT) Market: Focus on Method, Test, Platform, End User, Appli
The global NIPT market was valued at $2.52 billion in 2020 and is expected to reach $12.61...
Market Research Report
A quick peek into the report
Table of Contents
1.1 Inclusion and Exclusion
2.1 Key Questions Answered by the Research Study
3.1 Primary Data Sources
3.2 Secondary Data Sources
3.3 Market Estimation Model
3.4 Assumptions and Limitations
4.1 Introduction
4.2 Test Performed During Diagnosis
4.3 Market Footprint and Growth Potential
4.4 Future Potential
4.5 Impact of COVID-19 on Global Reproductive Genetics Market
4.6 COVID-19 Affecting Supply Chain of Global Reproductive Genetics Market
4.7 Interruption in Research and Clinical Development and Commercial Operation
4.7.1 Research and Clinical Development
4.7.2 Commercial Operation and Access
4.8 Navigating Crisis Recovery and Looking to the Future
5.1 Legal and Regulatory Framework
5.1.1 Overview
5.1.1.1 Regulatory Framework in the U.S.
5.2 Appropriate Use Criteria of Carrier Screening in the U.S.
5.2.1 Carrier Screening for Familial Disease
5.2.1.1 Fragile X Syndrome
5.2.2 Carrier Screening for Common and Ethnic Genetic Diseases
5.2.2.1 Cystic Fibrosis
5.2.2.2 Spinal Muscular Atrophy
5.2.2.3 Hemoglobinopathies
5.2.2.4 Ashkenazi Jewish Carrier Screening
5.2.3 Other Ethnicities
5.2.4 Regulatory Framework in the European Union
5.2.5 Germany
5.2.6 France
5.2.7 U.K.
5.2.8 Spain
5.3 Regulations in Asia-Pacific (APAC)
5.3.1 China
5.3.2 Japan
5.3.3 South Korea
Patent Landscape
7.1 Impact Analysis
7.2 Market Drivers
7.2.1 The Declining Cost of Genetic Sequencing Technologies
7.2.2 Increasing Awareness and Acceptance for Genetic Testing and Screening
7.2.3 Rising Emphasis on Early Detection and Prevention
7.2.4 Rising Maternal Age Leading to Pregnancy Complications
7.3 Market Restraints
7.3.1 Lack of regulations
7.3.2 Ethical and Social Issues
7.4 Market Opportunities
7.4.1 Shifting of Reimbursement Policies toward Enhanced Genetics Coverage
7.4.2 Rising Funding and Innovations
7.4.3 Increasing Consumer Demand
8.1 Overview
8.2 Key Developments and Strategies
8.3 New Offerings
8.4 Synergistic Activities
8.5 Product Approval
8.6 Business Expansion
8.7 Market Share Analysis
8.8 Growth-Share Analysis
9.1 Overview
9.2 Carrier Screening
9.3 Pre-Natal Screening
9.4 Pre-Implantation Genetic Testing
9.5 Infertility Genetic Testing
10.1 Overview
10.2 Kits
10.3 Laboratory Developed Tests (LDT)
10.4 Reagents and Consumables
11.1 Next-Generation Sequencing
11.2 Polymerase Chain Reaction
11.3 In Situ Hybridization (ISH/FISH)
11.4 Microarray
12.1 Overview
12.2 Aneuploidy
12.3 Structural Chromosomal Abnormality
12.4 Single Gene Disorder
12.5 Others
13.1 Overview
13.2 North America
13.2.1 North America: Market Dynamics
13.2.2 U.S.
13.2.3 Canada
13.3 Europe
13.3.1 Europe: Market Dynamics
13.3.2 U.K.
13.3.3 Germany
13.3.4 France
13.3.5 Italy
13.3.6 Spain
13.3.7 Rest-of-Europe
13.4 Asia-Pacific
13.4.1 Asia-Pacific: Market Dynamics
13.4.2 Japan
13.4.3 China
13.4.4 India
13.4.5 Australia
13.4.6 South Korea
13.4.7 Rest-of-Asia-Pacific
13.5 Latin America
13.5.1 Latin America: Market Dynamics
13.5.2 Brazil
13.5.3 Mexico
13.5.4 Rest-of-Latin-America
13.6 Rest-of-the-World
14.1 Overview
14.2 Agilent Technologies, Inc.
14.2.1 Company Overview
14.2.2 Role of Agilent Technologies, Inc. in the Global Reproductive Genetics Market
14.2.3 Financials
14.2.4 SWOT Analysis
14.3 BGI
14.3.1 Company Overview
14.3.2 Role of BGI Group in Global Reproductive Genetics Market
14.3.3 SWOT Analysis
14.4 CENTOGENE AG
14.4.1 Company Overview
14.4.2 Role of Centogene AG in the Global Reproductive Genetics Market
14.4.3 SWOT Analysis
14.5 Fulgent Genetics, Inc.
14.5.1 Company Overview
14.5.2 Role of Fulgent Genetics, Inc. in the Global Reproductive Genetics Market
14.5.3 Financials
14.5.4 SWOT Analysis
14.6 F. Hoffmann-La Roche Ltd
14.6.1 Company Overview
14.6.2 Role of F. Hoffman-LA Roche Ltd in the Global Reproductive Genetics Market
14.6.3 Financials
14.6.4 SWOT Analysis
14.7 Igenomix
14.7.1 Company Overview
14.7.2 Role of Igenomix in the Global Reproductive Genetics Market
14.7.3 SWOT Analysis
14.8 Illumina, Inc.
14.8.1 Company Overview
14.8.2 Role of Illumina, Inc. in the Global Reproductive Genetics Market
14.8.3 Financials
14.8.4 SWOT Analysis
14.9 Invitae Corporation
14.9.1 Company Overview
14.9.2 Role of Invitae Corporation in the Global Reproductive Genetics Market
14.9.3 Financials
14.9.4 SWOT Analysis
14.10 Laboratory Corporation of America Holdings
14.10.1 Company Overview
14.10.2 Role of Laboratory Corporation of America Holdings in the Global Reproductive Genetics Market
14.10.3 Financials
14.10.4 SWOT Analysis
14.11 PerkinElmer, Inc.
14.11.1 Company Overview
14.11.2 Role of PerkinElmer, Inc. in the Global Reproductive Genetics Market
14.11.3 Financials
14.11.4 SWOT Analysis
14.12 Myriad Genetics, Inc.
14.12.1 Company Overview
14.12.2 Role of Myriad Genetics, Inc. in the Global Reproductive Genetics Market
14.12.3 Financials
14.12.4 Key Insights About Financial Health of the Company
14.12.5 SWOT Analysis
14.13 OPKO Health, Inc.
14.13.1 Company Overview
14.13.2 Role of OPKO Health, Inc. in the Global Reproductive Genetics Market
14.13.3 Financials
14.13.4 SWOT Analysis
14.14 Quest Diagnostics
14.14.1 Company Overview
14.14.2 Role of Quest Diagnostics in the Global Reproductive Genetics Market
14.14.3 Financials
14.14.4 SWOT Analysis
14.15 QIAGEN N.V.
14.15.1 Company Overview
14.15.2 Role of QIAGEN N.V. in the Global Reproductive Genetics Market
14.15.3 Financials
14.15.4 SWOT Analysis
14.16 Thermo Fisher Scientific Inc.
14.16.1 Company Overview
14.16.2 Role of Thermo Fisher Scientific Inc. in the Global Reproductive Genetics Market
14.16.3 Financials
14.16.4 SWOT Analysis
Table 5.1: Regulatory Bodies Governing Genetic Testing
Table 7.1: Declining Cost of Genome
Table 12.1: Incidence of Aneuploidies
Table 12.2: Global Incidence of Major Single Gene Disorders
Figure 1 : Global Prevalence of Congenital Abnormalities (2015-2019)
Figure 2: Global Reproductive Genetics Market, 2020-2030
Figure 3: Market Drivers, Market Opportunities and Market Restraints
Figure 4: Share of Key Developments and Strategies, Global Reproductive Genetics Market, January 2017-February 2021
Figure 5: Growth-Share Analysis: Global Reproductive Genetics Market (by Company), 2020
Figure 2.1: Global Reproductive Genetics Market Segmentation
Figure 3.1: Global Reproductive Genetics Market Research Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 4.1: Type of Reproductive Genetic Tests
Figure 4.2: Positive and Negative Impact of COVID-19 on Global Reproductive Genetics Market
Figure 4.3: Pre-COVID-19 and Post-COVID-19 Scenario, Global Reproductive Genetics Market, 2020-2025
Figure 4.4: Measure to Navigate Crisis Recovery
Figure 6.1: Number of Patents (by Year), 2016-2020
Figure 7.1: Impact Analysis
Table 7.1: Declining Cost of Genome
Figure 8.1: Share of Key Developments and Strategies, January 2017-March 2021
Figure 8.2: Product Offering Share (by Company), January 2017-January 2021
Figure 8.3: Synergistic Activities Share (by Company), January 2017-January 2021
Figure 8.4: Product Approval Share (by Company), January 2017-January 2021
Figure 8.5: Business Expansion Activities (by Company), January 2017-January 2021
Figure 8.6: Market Share Analysis: Global Reproductive Genetics Market Share Analysis (by Company), 2020
Figure 8.7: Growth-Share Analysis: Global Reproductive Genetics Market (by Company), 2020
Figure 9.1: Share of Global Reproductive Genetics Market (by Procedure Type), $Million, 2020-2030
Figure 9.2: Global Reproductive Genetics Market (Carrier Screening), $Million, 2020-2030
Figure 9.3: Global Reproductive Genetics Market (Pre-Natal Screening), $Million,2020-2030
Figure 9.4: Global Reproductive Genetics Market (Pre-Implantation Genetic Testing), $Million,2020-2030
Figure 9.5: Global Reproductive Genetics Market (Infertility Genetic Testing), $Million, 2020-2030
Figure 10.1: Share of Global Reproductive Genetics Market (by Product Type), $Million, 2020-2030
Figure 10.2: Global Reproductive Genetics Market (Kits), $Million, 2020-2030
Figure 10.3: Reproductive Genetics Market (LDT), $Million, 2020-2030
Figure 10.4: Global Reproductive Genetics Market (Reagents and Consumables), $Million, 2020-2030
Figure 11.1: Share of Global Reproductive Genetics Market (by Technology), $Million, 2020-2030
Figure 11.2: Global Reproductive Genetics Market (Next-Generation Sequencing), $Million, 2020-2030
Figure 11.3: Global Reproductive Genetics Market (PCR), $Million, 2020-2030
Figure 11.4: Global Reproductive Genetics Market (ISH), $Million, 2020-2030
Figure 11.5: Global Reproductive Genetics Market (Microarray), $Million, 2020-2030
Figure 12.1: Global Reproductive Genetics Market, $Million, 2020 and 2030
Figure 12.2: Global Reproductive Genetics Market (Aneuploidy), $Million, 2020-2030
Figure 12.3: Types of Structural Chromosomal Abnormality
Figure 12.4: Global Reproductive Genetics Market (Structural Chromosomal Abnormality), $Million, 2020-2030
Figure 12.5: Pedigree Analysis of Inheritance Pattern of a Dominant Disease
Figure 12.6: Pedigree Analysis of Inheritance Pattern of a Recessive Disease
Figure 12.7: Global Reproductive Genetics Market (Single Gene Disorders), $Million, 2020-2030
Figure 12.8: Global Reproductive Genetics Market (by Others), $Million, 2020-2030
Figure 13.1: Global Reproductive Genetics Market (by Region)
Figure 13.2: North America Reproductive Genetics Market, $Million ,(2020-2030)
Figure 13.3: North America: Market Dynamics
Figure 13.4: North America Reproductive Genetics Market (by Country), $Million, 2020-2030
Figure 13.5: U.S. Reproductive Genetics Market, $Million, 2020-2030
Figure 13.6: Canada Reproductive Genetics Market, $Million, 2020-2030
Figure 13.7: Europe Reproductive Genetics Market, $Million, 2020-2030
Figure 13.8: Europe: Market Dynamics
Figure 13.9: Europe: Reproductive Genetics Market (by Country), 2020 and 2030
Figure 13.10: U.K. Reproductive Genetics Market, $Million, 2020-2030
Figure 13.11: Germany Reproductive Genetics Market, $Million, 2020-2030
Figure 13.12: Number of Live Births in Germany (2012-2018)
Figure 13.13: France Reproductive Genetics Market, $Million, 2020-2030
Figure 13.14: Italy Reproductive Genetics Market, $Million, 2020-2030
Figure 13.15: Spain Reproductive Genetics Market, $Million, 2020-2030
Figure 13.16: Rest-of-Europe Reproductive Genetics Market, $Million, 2020-2030
Figure 13.17: Asia-Pacific Reproductive Genetics Market, $Million, 2020-2030
Figure 13.18: Asia-Pacific: Market Dynamics
Figure 13.19: Asia-Pacific Reproductive Genetics Market (by Country), 2020 and 2030
Figure 13.20: Japan Reproductive Genetics Market, $Million, 2020-2030
Figure 13.21: China Reproductive Genetics Market, $Million, 2020-2030
Figure 13.22: India Reproductive Genetics Market, $Million, 2020-2030
Figure 13.23: Australia Reproductive Genetics Market, $Million, 2020-2030
Figure 13.24: South Korea Reproductive Genetics Market, $Million, 2020-2030
Figure 13.25: Rest-of-Asia-Pacific Reproductive Genetics Market, $Million, 2020-2030
Figure 13.26: Latin America Reproductive Genetics Market, $Million, 2020-2030
Figure 13.27: Latin America: Market Dynamics
Figure 13.28: Latin America Reproductive Genetics Market (by Country), 2020 and 2030
Figure 13.29: Brazil Reproductive Genetics Market, $Million, 2020-2030
Figure 13.30: Mexico Reproductive Genetics Market, $Million, 2020-2030
Figure 13.31: Rest-of-Latin-America Reproductive Genetics Market, $Million, 2020-2030
Figure 13.32: Rest-of-the-World Reproductive Genetics Market, $Million, 2020-2030
Figure 14.1: Shares of Key Company Profiles
Figure 14.2: Agilent Technologies, Inc.: Overall Product Offerings
Figure 14.3: Agilent Technologies, Inc.: Overall Financials, 2018-2020
Figure 14.4: Agilent Technologies, Inc.: Net Revenue (by Business Segment), 2018-2020
Figure 14.5: Agilent Technologies, Inc.: Revenue (by Region), 2018-2020
Figure 14.6: Agilent Technologies, Inc.: Research and Development Expense, 2018-2020
Figure 14.7: Agilent Technologies, Inc.: SWOT Analysis
Figure 14.8: BGI Group.: Overall Product Portfolio
Figure 14.9: BGI Group: SWOT Analysis
Figure 14.10: CENTOGENE AG: Overall Product Offerings
Figure 14.11: Centogene AG: SWOT Analysis
Figure 14.12: Fulgent Genetics, Inc..: Overall Product Offerings
Figure 14.13: Fulgent Genetics, Inc.: Overall Financials, 2018-2020
Figure 14.14: Fulgent Genetics, Inc.: Net Revenue (by Region), 2018-2020
Figure 14.15: Fulgent Genetics, Inc.: Research and Development Expense, 2018-2020
Figure 14.16: Fulgent Genetics, Inc.: SWOT Analysis
Figure 14.17: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 14.18: F. Hoffmann-La Roche Ltd: Overall Financials, 2018-2020
Figure 14.19: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2018-2020
Figure 14.20: Hoffmann-La Roche Ltd: Revenue (by Region), 2018-2020
Figure 14.21: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2018-2020
Figure 14.22: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 14.23: Igenomix : Overall Product Portfolio
Figure 14.24: Igenomix.: SWOT Analysis
Figure 14.25: Illumina, Inc.: Overall Product Portfolio
Figure 14.26: Illumina, Inc.: Overall Financials, 2018-2020
Figure 14.27: Illumina, Inc.: Revenue (by Segment), 2018-2020
Figure 14.28: Illumina, Inc.: Revenue (by Region), 2018-2020
Figure 14.29: Illumina, Inc.: R&D Expenditure, 2018-2020
Figure 14.30: Illumina, Inc.: SWOT Analysis
Figure 14.31: Invitae Corporation: Overall Product Offerings
Figure 14.32: Invitae Corporation: Overall Financials, 2018-2020
Figure 14.33: Invitae Corporation: Revenue (by Segment), 2018-2020
Figure 14.34: Invitae Corporation: Revenue (by Region), 2018-2020
Figure 14.35: Invitae Corporation: R&D Expenditure, 2018-2020
Figure 14.36: Invitae Corporation: SWOT Analysis
Figure 14.37: Laboratory Corporation of America Holdings: Overall Product Portfolio
Figure 14.38: Laboratory Corporation of America Holdings: Overall Financials, 2018-2020
Figure 14.39: Laboratory Corporation of America Holdings: Revenue (by Segment), 2018-2020
Figure 14.40: Laboratory Corporation of America Holdings: Revenue (by Region), 2019
Figure 14.41: Laboratory Corporation of America Holdings: SWOT Analysis
Figure 14.42: PerkinElmer, Inc.: Overall Product Offerings
Figure 14.43: PerkinElmer, Inc: Overall Financials, 2018-2020
Figure 14.44: PerkinElmer, Inc.: Revenue (by Segment), 2018-2020
Figure 14.45: PerkinElmer, Inc.: R&D Expenditure, 2018-2020
Figure 14.46: PerkinElmer, Inc.: SWOT Analysis
Figure 14.47: Myriad Genetics, Inc.: Product Portfolio
Figure 14.48: Myriad Genetics, Inc.: Overall Financials, 2018-2020
Figure 14.49: Myriad Genetics, Inc.: Revenue (by Business Segment), 2018-2020
Figure 14.50: Myriad Genetics, Inc.: R&D Expenditure, 2018-2020
Figure 14.51: Myriad Genetics, Inc.: SWOT Analysis
Figure 14.52: OPKO Health, Inc.: Overall Product Offerings
Figure 14.53: OPKO Health, Inc.: Overall Financials, 2017-2019
Figure 14.54: OPKO Health, Inc: Net Revenue (by Business Segment), 2017-2019
Figure 14.55: OPKO Health, Inc.: Net Revenue (by Region), 2017-2019
Figure 14.56: OPKO Health, Inc.: Research and Development Expenditure, 2017-2019
Figure 14.57: OPKO Health, Inc.: SWOT Analysis
Figure 14.58: Quest Diagnostics Incorporated: Overall Product Offerings
Figure 14.59: Quest Diagnostics Incorporated: Overall Financials, 2018-2020
Figure 14.60: Quest Diagnostics Incorporated: Revenue (by Business Segment), 2018-2020
Figure 14.61: Quest Diagnostics Incorporated: SWOT Analysis
Figure 14.62: QIAGEN N.V.: Overall Product Portfolio
Figure 14.63: QIAGEN N.V.: Overall Financials, 2017-2019
Figure 14.64: QIAGEN N.V.: Revenue (by Segment), 2017-2019
Figure 14.65: QIAGEN N.V.: Revenue (by Region), 2017-2019
Figure 14.66: QIAGEN N.V.: R&D Expenditure, 2017-2019
Figure 14.67: QIAGEN N.V.: SWOT Analysis
Figure 14.68: Thermo Fisher Scientific Inc.: Overall Product Portfolio
Figure 14.69: Thermo Fisher Scientific Inc.: Overall Financials, 2018-2020
Figure 14.70: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2018-2020*
Figure 14.72: Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020
Figure 14.73: Thermo Fisher Scientific Inc.: SWOT Analysis
Report Description
|
Market Report Coverage - Reproductive Genetics |
|||
|
Base Year |
2020 |
Market Size in 2020 |
$4,402.8 Million |
|
Forecast Period |
2021-2030 |
Value Projection and Estimation by 2030 |
$12,930.0 Million |
|
CAGR During Forecast Period |
12.38% |
Number of Tables |
04 |
|
Number of Pages |
216 |
Number of Figures |
148 |
|
Research Hours |
600 |
|
|
|
Market Segmentation |
• Procedure Type– Pre-Natal Screening, Pre-Implantation Genetic Testing, Infertility Genetic Testing, Carrier Screening • Product Type– Kits, LDTs, Reagents and Consumables, Systems and Instruments • Application Type– Aneuploidy, Single Gene Disorders, Structural Abnormalities, Others • Technology– PCR, Sequencing, In-Situ Hybridization (ISH), Comparative Genomic Hybridization (CGH) |
||
|
Regional Segmentation |
• North America– U.S., Canada • Europe– U.K., Germany, France, Italy, Spain, Rest-of Europe • Asia-Pacific– Japan, China, India, South Korea, Australia, Rest-of-Asia-Pacific • Latin America– Brazil, Mexico, Rest-of-Latin-America • Rest-of-the-World |
||
|
Growth Drivers |
• Declining Cost of Genetic Sequencing Technologies • Increasing Awareness and Acceptance for Genetic Testing and Screening • Rising Emphasis on Early Detection and Prevention • Rising Maternal Age Leading to Pregnancy Complications |
||
|
Market Challenges |
• Lack of Regulations • Ethical and Social Issues |
||
|
Market Opportunities |
• Shifting of Reimbursement Policies toward Enhanced Genetic Testing Coverage • Rising Funding and Innovations • Increasing Consumer Demand |
||
|
Key Companies Profiled |
Illumina, Inc., Myriad Genetics, Inc., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics, Natera, Inc., BGI, CooperSurgical, Inc., Centogene AG, Invitae Corporation, Igenomix, and Eurofins Scientific |
||
Key Questions Answered in this Report:
• What are the most common genetic causes of genetic defects at birth globally?
• What are the emerging technologies that can take over the current technologies for genetic testing within the global reproductive genetics market?
• How are the key market players performing research investments in the respective market?
• What are the major strategies opted by the key players for advancing in the global reproductive genetics market?
• What are the regulations pertaining to the reproductive genetics market among different regions and their impact on the respective market?
• What are the initiatives implemented by different government bodies regulating the development and commercialization of reproductive genetic tests and associated platforms?
• How has COVID-19 impacted the global reproductive genetics market?
• How will the urgency of the pandemic influence the global reproductive genetics market?
• What are the leading companies dominating the global reproductive genetics market?
• What is the reimbursement scenario of the tests offered in the global reproductive genetics market?
• Based on the procedure type, which global reproductive genetics market procedure type is anticipated to witness a massive rise in demand in the forecast period 2021-2030?
• How is each segment of the global reproductive genetics market expected to grow during the forecast period, and what is the revenue expected to be generated by each of the segments by the end of 2030?
• How is the global reproductive genetics industry anticipated to evolve during the forecast period 2021-2030?
• What are the leading trends and consumer preferences witnessed in the global reproductive genetics market?
Market Overview
Reproductive genetics is a branch of science that contributes to predicting and preventing a genetic disorder during the reproductive procedure (both natural and artificial). It refers to the genetic tests and procedures that are used to offer prospective parents any needful information about the probabilities of having a child with any specific genetic disorder.
The advancements in genomic technologies and their implementation within clinical medicine have led to an expanded usage such as carrier screening, diagnosis of genetic disorders prior to implantation, and identifying the causes of infertility.
The respective genetic testing helps in analyzing genetic material such as chromosomes, genes, DNA, RNA, and gene products for accessing genetic changes that have a likelihood of causing any genetic disease after pregnancy in either mother or child.
The global reproductive genetics market is poised to have substantial investment and growth as the demand for such testing escalates, reimbursement improves, and the technology expands to additional, novel applications.
There has been steady progress in the demand for various methods of reproductive genetic testing. For instance, there has been a global explosion in the utilization of additional non-invasive prenatal testing (NIPT) and the continuous expansion of upstream preconception testing (PGD/PGS) and downstream neonatal screening and genetic disorder testing. Further, there has been a rise in the availability of next-generation technologies and panels that allow the screening of genetic disorders at an early stage in the fetus during pregnancy. However, some of these tests are often an out-of-pocket expense for patients, but the demand for genetic information, declining cost of sequencing, and rise in mixed-ethnicity population is expected to propel the growth of the market.
Within the research report, the market has been segmented on the basis of procedure type, product type, application type, technology, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The global reproductive genetics market consists of numerous large-and small-scale manufacturers and service providers. Presently, with the increasing rate of molecular advancements and the rise in the adoption of genetic tests, there has been an expansion of opportunities for the reproductive genetics market. Some of the strategies opted by the key players within the market are new product offerings, product approvals, partnerships and alliances, mergers and acquisitions, and business expansions.
In the five years (January 2017-February 2021), the market witnessed 23 product offerings, five product approvals, 16 partnerships and alliances, nine mergers and acquisitions, and five business expansions. The increasing awareness for genetic testing with an answer for genetic abnormalities caused has majorly attributed to the growing prominence for reproductive genetic testing.
On the basis of region, North America holds the largest share in the global reproductive genetics market due to improved healthcare infrastructure, rise in awareness, and improvised reimbursement policies in the region. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.
Global Reproductive Genetics Market
Focus on Procedure Type, Product Type, Technology, Application Type, Country Data (15 countries) - Analysis and Forecast, 2020-2030
Some Faq's
Frequently Asked Questions
In 2020, the global reproductive genetics market generated $4.40 billion and is projected to reach the mark of $12.93 billion by 2030.
Factors such as the declining cost of genetic sequencing technologies, increasing awareness and acceptance for genetic testing and screening, rising emphasis on early detection and prevention, and rising maternal age leading to pregnancy complications, favour the growth of this emerging tech.
Lack of regulations and, ethical and social issues, are some challenges that hinder the adoption of reproductive genetics by healthcare institutions/companies.
Based on region, North America dominates the global reproductive genetics industry due to improved healthcare infrastructure, rise in awareness, and improvised reimbursement policies in the region.
Major players involved in the reproductive genetics market are Illumina, Inc., Myriad Genetics, Inc., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics, Natera, Inc., BGI, CooperSurgical, Inc., Centogene AG.
Similar Product
You may also like
Published Year: 2019
Global Carrier Screening Market – Analysis and Forecast, 2019-2029: Focus on Product Type, Technol
The global carrier screening market was valued at $846.9 million in 2018 and is estimated to...